NEOS Investment Management LLC Purchases 223,163 Shares of Pfizer Inc. $PFE

NEOS Investment Management LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 48.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 681,017 shares of the biopharmaceutical company’s stock after buying an additional 223,163 shares during the quarter. NEOS Investment Management LLC’s holdings in Pfizer were worth $17,352,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Curio Wealth LLC increased its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer during the second quarter valued at about $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter worth approximately $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new stake in Pfizer during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on PFE. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. UBS Group initiated coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price for the company. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Citigroup started coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.00.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.37 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a fifty day moving average of $25.88 and a 200 day moving average of $25.26. The firm has a market cap of $155.62 billion, a PE ratio of 20.13 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.